<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Elevai Labs Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/m1XTUjN4ingSwRd04cXIZw==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2024, Elevai Labs Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Mon, 04 Nov 2024 22:45:39 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/04/2974528/0/en/Elevai-Labs-Inc-Announces-Update-and-Extension-of-Pending-Offer-to-Exchange.html</guid> <link>https://www.globenewswire.com/news-release/2024/11/04/2974528/0/en/Elevai-Labs-Inc-Announces-Update-and-Extension-of-Pending-Offer-to-Exchange.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange</title> <description><![CDATA[Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange]]></description> <pubDate>Mon, 04 Nov 2024 22:45 GMT</pubDate> <dc:identifier>2974528</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 04 Nov 2024 22:45 GMT</dc:modified> <dc:subject>Major shareholder announcements</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/22/2967072/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Engages-Leading-Contract-Research-Organization-CRO-to-Support-Regulatory-Planning-Efforts-and-Pre-IND-Meeting-with-the-Food-and-D.html</guid> <link>https://www.globenewswire.com/news-release/2024/10/22/2967072/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Engages-Leading-Contract-Research-Organization-CRO-to-Support-Regulatory-Planning-Efforts-and-Pre-IND-Meeting-with-the-Food-and-D.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity</title> <description><![CDATA[Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity]]></description> <pubDate>Tue, 22 Oct 2024 13:54 GMT</pubDate> <dc:identifier>2967072</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 22 Oct 2024 13:54 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Mounjaro</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>nasdaq</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>Ozempic</dc:keyword> <dc:keyword>semaglutide</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/21/2966100/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Highlights-Past-Positive-Preclinical-Data-Showing-Potential-of-EL-32-A-Dual-Myostatin-Activin-A-Blocker-For-the-Treatment-of-Obes.html</guid> <link>https://www.globenewswire.com/news-release/2024/10/21/2966100/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Highlights-Past-Positive-Preclinical-Data-Showing-Potential-of-EL-32-A-Dual-Myostatin-Activin-A-Blocker-For-the-Treatment-of-Obes.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity</title> <description><![CDATA[Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl]]></description> <pubDate>Mon, 21 Oct 2024 11:30 GMT</pubDate> <dc:identifier>2966100</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 21 Oct 2024 11:30 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Mounjaro</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>Ozempic</dc:keyword> <dc:keyword>semaglutide</dc:keyword> <dc:keyword>wegovy</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/04/2958524/0/en/Elevai-Labs-Inc-Commences-Offer-to-Exchange-Up-to-15-000-000-shares-of-Common-Stock-For-Shares-of-Non-Tradable-Locked-Up-Series-B-Preferred-Stock.html</guid> <link>https://www.globenewswire.com/news-release/2024/10/04/2958524/0/en/Elevai-Labs-Inc-Commences-Offer-to-Exchange-Up-to-15-000-000-shares-of-Common-Stock-For-Shares-of-Non-Tradable-Locked-Up-Series-B-Preferred-Stock.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock</title> <description><![CDATA[Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock]]></description> <pubDate>Fri, 04 Oct 2024 21:08 GMT</pubDate> <dc:identifier>2958524</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Fri, 04 Oct 2024 21:09 GMT</dc:modified> <dc:subject>Changes in share capital and votes</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/03/2957992/0/en/REPEAT-Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Recept.html</guid> <link>https://www.globenewswire.com/news-release/2024/10/03/2957992/0/en/REPEAT-Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Recept.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations</title> <description><![CDATA[Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,]]></description> <pubDate>Thu, 03 Oct 2024 19:45 GMT</pubDate> <dc:identifier>2957992</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Thu, 03 Oct 2024 19:45 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Patents</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>finance</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Mounjaro</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>Ozempic</dc:keyword> <dc:keyword>semaglutide</dc:keyword> <dc:keyword>wegovy</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/03/2957611/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Receptor-Agon.html</guid> <link>https://www.globenewswire.com/news-release/2024/10/03/2957611/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Receptor-Agon.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations</title> <description><![CDATA[Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,]]></description> <pubDate>Thu, 03 Oct 2024 11:30 GMT</pubDate> <dc:identifier>2957611</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Thu, 03 Oct 2024 11:30 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Patents</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>Obesity</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/02/2956947/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Launch-of-Clinical-Study-Combining-Its-Flagship-Topical-Exosome-Skincare-Products-with-a-Medical-Aesthetic-Energy-Device.html</guid> <link>https://www.globenewswire.com/news-release/2024/10/02/2956947/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Launch-of-Clinical-Study-Combining-Its-Flagship-Topical-Exosome-Skincare-Products-with-a-Medical-Aesthetic-Energy-Device.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic]]></description> <pubDate>Wed, 02 Oct 2024 12:30 GMT</pubDate> <dc:identifier>2956947</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 02 Oct 2024 12:31 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>regenerative</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/23/2951407/0/en/Elevai-Labs-Inc-Announces-Pricing-of-8-0-Million-Public-Offering.html</guid> <link>https://www.globenewswire.com/news-release/2024/09/23/2951407/0/en/Elevai-Labs-Inc-Announces-Pricing-of-8-0-Million-Public-Offering.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering</title> <description><![CDATA[<p align="justify">NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.<br></p>]]></description> <pubDate>Mon, 23 Sep 2024 12:45 GMT</pubDate> <dc:identifier>2951407</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 23 Sep 2024 12:45 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/10/2943558/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Results-for-E-Series-Exosome-Technology-in-Potential-Melasma-Applications.html</guid> <link>https://www.globenewswire.com/news-release/2024/09/10/2943558/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Results-for-E-Series-Exosome-Technology-in-Potential-Melasma-Applications.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications]]></description> <pubDate>Tue, 10 Sep 2024 11:30 GMT</pubDate> <dc:identifier>2943558</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 10 Sep 2024 11:31 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/03/2939574/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Encouraging-Data-Results-Indicating-Potential-for-Hair-Restoration-Using-Proprietary-Exosome-Technology.html</guid> <link>https://www.globenewswire.com/news-release/2024/09/03/2939574/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Encouraging-Data-Results-Indicating-Potential-for-Hair-Restoration-Using-Proprietary-Exosome-Technology.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary]]></description> <pubDate>Tue, 03 Sep 2024 11:30 GMT</pubDate> <dc:identifier>2939574</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 03 Sep 2024 11:30 GMT</dc:modified> <dc:subject>Partnerships</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>hair and scalp care</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/08/28/2936908/0/en/Elevai-Labs-Inc-Files-Combination-Patents-with-Yuva-Biosciences-for-Breakthrough-Hair-and-Scalp-Care-Technology-Utilizing-YuvaBio-Y100-Mitochondrial-Innovation-and-Elevai-Exosomes.html</guid> <link>https://www.globenewswire.com/news-release/2024/08/28/2936908/0/en/Elevai-Labs-Inc-Files-Combination-Patents-with-Yuva-Biosciences-for-Breakthrough-Hair-and-Scalp-Care-Technology-Utilizing-YuvaBio-Y100-Mitochondrial-Innovation-and-Elevai-Exosomes.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™</title> <description><![CDATA[Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria]]></description> <pubDate>Wed, 28 Aug 2024 11:30 GMT</pubDate> <dc:identifier>2936908</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 28 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Patents</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>hair and scalp care</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>hair loss</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/08/26/2935402/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Data-Results-with-Completion-of-Clinical-Study-of-Elevai-Enfinity-Topical-Exosome-Serum.html</guid> <link>https://www.globenewswire.com/news-release/2024/08/26/2935402/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Data-Results-with-Completion-of-Clinical-Study-of-Elevai-Enfinity-Topical-Exosome-Serum.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai EnfinityTM]]></description> <pubDate>Mon, 26 Aug 2024 11:30 GMT</pubDate> <dc:identifier>2935402</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 26 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>regenerative</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/08/19/2932144/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Research-Inc-Announces-Preliminary-Positive-Research-Data-Highlighting-the-Potential-of-Proprietary-Exosome-Technology-for-Skin-Health-Application.html</guid> <link>https://www.globenewswire.com/news-release/2024/08/19/2932144/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Research-Inc-Announces-Preliminary-Positive-Research-Data-Highlighting-the-Potential-of-Proprietary-Exosome-Technology-for-Skin-Health-Application.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data]]></description> <pubDate>Mon, 19 Aug 2024 13:00 GMT</pubDate> <dc:identifier>2932144</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 19 Aug 2024 13:00 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/08/14/2930133/0/en/Elevai-Labs-Inc-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html</guid> <link>https://www.globenewswire.com/news-release/2024/08/14/2930133/0/en/Elevai-Labs-Inc-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update</title> <description><![CDATA[Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update]]></description> <pubDate>Wed, 14 Aug 2024 13:05 GMT</pubDate> <dc:identifier>2930133</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 14 Aug 2024 13:06 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/07/30/2921052/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-Continues-to-Advance-its-Scientific-Advisory-Board-with-the-Appointment-of-Orian-Shirihai-MD-PhD.html</guid> <link>https://www.globenewswire.com/news-release/2024/07/30/2921052/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-Continues-to-Advance-its-Scientific-Advisory-Board-with-the-Appointment-of-Orian-Shirihai-MD-PhD.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD]]></description> <pubDate>Tue, 30 Jul 2024 13:00 GMT</pubDate> <dc:identifier>2921052</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 30 Jul 2024 13:01 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>Obesity</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/28/2905886/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Announces-The-Elevai-S-Series-Hair-and-Scalp-Care-Product-Line.html</guid> <link>https://www.globenewswire.com/news-release/2024/06/28/2905886/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Announces-The-Elevai-S-Series-Hair-and-Scalp-Care-Product-Line.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line]]></description> <pubDate>Fri, 28 Jun 2024 13:00 GMT</pubDate> <dc:identifier>2905886</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Fri, 28 Jun 2024 13:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>regenerative</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> <dc:keyword>hair loss</dc:keyword> <dc:keyword>hair and scalp care</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/26/2904555/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-to-Debut-Upcoming-New-Product-Line-at-The-Aesthetic-Show-2024.html</guid> <link>https://www.globenewswire.com/news-release/2024/06/26/2904555/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-to-Debut-Upcoming-New-Product-Line-at-The-Aesthetic-Show-2024.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024</title> <description><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024]]></description> <pubDate>Wed, 26 Jun 2024 13:00 GMT</pubDate> <dc:identifier>2904555</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 26 Jun 2024 13:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/14/2899006/0/en/Elevai-Labs-Forms-New-Scientific-Advisory-Board-for-its-Weight-Loss-Programs.html</guid> <link>https://www.globenewswire.com/news-release/2024/06/14/2899006/0/en/Elevai-Labs-Forms-New-Scientific-Advisory-Board-for-its-Weight-Loss-Programs.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs</title> <description><![CDATA[Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs]]></description> <pubDate>Fri, 14 Jun 2024 13:00 GMT</pubDate> <dc:identifier>2899006</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Fri, 14 Jun 2024 13:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/29/2889949/0/en/Elevai-Labs-Subsidiary-Elevai-Skincare-to-Present-at-the-Beauty-Through-Science-Conference-in-Stockholm.html</guid> <link>https://www.globenewswire.com/news-release/2024/05/29/2889949/0/en/Elevai-Labs-Subsidiary-Elevai-Skincare-to-Present-at-the-Beauty-Through-Science-Conference-in-Stockholm.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm</title> <description><![CDATA[Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm]]></description> <pubDate>Wed, 29 May 2024 13:00 GMT</pubDate> <dc:identifier>2889949</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 29 May 2024 13:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/22/2886862/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-to-Present-at-the-UCLA-LA-BEST-2024-Conference.html</guid> <link>https://www.globenewswire.com/news-release/2024/05/22/2886862/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-to-Present-at-the-UCLA-LA-BEST-2024-Conference.html</link> <category domain="https://www.globenewswire.com/rss/stock">Nasdaq:ELAB</category> <category domain="https://www.globenewswire.com/rss/ISIN">US28622K1043</category> <title>Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference</title> <description><![CDATA[Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference]]></description> <pubDate>Wed, 22 May 2024 20:15 GMT</pubDate> <dc:identifier>2886862</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 22 May 2024 20:15 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>finance</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> </item> </channel> </rss>